AGL 40.30 Increased By ▲ 0.30 (0.75%)
AIRLINK 127.29 Increased By ▲ 0.25 (0.2%)
BOP 6.67 No Change ▼ 0.00 (0%)
CNERGY 4.49 Decreased By ▼ -0.02 (-0.44%)
DCL 8.64 Increased By ▲ 0.09 (1.05%)
DFML 41.89 Increased By ▲ 0.45 (1.09%)
DGKC 87.90 Increased By ▲ 1.05 (1.21%)
FCCL 32.81 Increased By ▲ 0.53 (1.64%)
FFBL 64.87 Increased By ▲ 0.07 (0.11%)
FFL 10.26 Increased By ▲ 0.01 (0.1%)
HUBC 109.75 Increased By ▲ 0.18 (0.16%)
HUMNL 14.82 Increased By ▲ 0.14 (0.95%)
KEL 5.13 Increased By ▲ 0.08 (1.58%)
KOSM 7.54 Increased By ▲ 0.08 (1.07%)
MLCF 41.84 Increased By ▲ 0.46 (1.11%)
NBP 59.68 Decreased By ▼ -0.73 (-1.21%)
OGDC 194.98 Increased By ▲ 4.88 (2.57%)
PAEL 28.28 Increased By ▲ 0.45 (1.62%)
PIBTL 7.82 Decreased By ▼ -0.01 (-0.13%)
PPL 152.50 Increased By ▲ 2.44 (1.63%)
PRL 26.65 Decreased By ▼ -0.23 (-0.86%)
PTC 16.19 Increased By ▲ 0.12 (0.75%)
SEARL 84.15 Decreased By ▼ -1.85 (-2.15%)
TELE 7.65 Decreased By ▼ -0.06 (-0.78%)
TOMCL 35.45 Increased By ▲ 0.04 (0.11%)
TPLP 8.17 Increased By ▲ 0.05 (0.62%)
TREET 16.17 Decreased By ▼ -0.24 (-1.46%)
TRG 52.80 Decreased By ▼ -0.49 (-0.92%)
UNITY 26.50 Increased By ▲ 0.34 (1.3%)
WTL 1.25 Decreased By ▼ -0.01 (-0.79%)
BR100 9,953 Increased By 69.1 (0.7%)
BR30 30,951 Increased By 351.4 (1.15%)
KSE100 93,901 Increased By 545.4 (0.58%)
KSE30 29,088 Increased By 157.5 (0.54%)

India's largest drugmaker Sun Pharmaceutical Industries Ltd reported a near-doubling in fourth-quarter profit, although that missed analysts' estimates as weakness in emerging markets outweighed higher sales in India and the United States.
Net profit for the world's fifth-largest generic drugs maker in the January-March quarter jumped to 17.1 billion rupees ($255 million) from 8.9 billion rupees in the same period a year earlier. But that was below a Thomson Reuters StarMine SmartEstimate of 19.14 billion rupees.
While US sales were up 19 percent and India sales rose 17 percent, sales in emerging markets that include Brazil, Mexico, Russia and South Africa were flat due to adverse currency rates, the company said.
Sales in what Sun Pharma calls "rest of the world markets" that include Australia and New Zealand as well as some countries in Western Europe fell 6 percent as it decided to not participate in some "non-remunerative" businesses.

Copyright Reuters, 2016

Comments

Comments are closed.